Novo Nordisk to Evaluate Vivani Medical's NPM-139 Semaglutide Implant for Weight Management
VANI sits 54% above its 52-week low of $0.923.
Summary
Vivani Medical announced an agreement for Novo Nordisk to internally evaluate its NPM-139 semaglutide implant for chronic weight management. This non-exclusive collaboration is a significant validation for Vivani's NanoPortal™ technology and its lead GLP-1 product candidate. It follows recent positive first-in-human trial results and regulatory approval for a Phase 1 study for NPM-139. Partnering with a major pharmaceutical company like Novo Nordisk, a leader in the GLP-1 market, could materially de-risk Vivani's development program and potentially lead to future licensing opportunities. Vivani expects to initiate its own Phase 1 study for NPM-139 in mid-2026.
At the time of this announcement, VANI was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.1M. The 52-week trading range was $0.92 to $1.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.